Live imaging of transforming growth factor-β activated kinase 1 activation in Lewis lung carcinoma 3LL cells implanted into syngeneic mice and treated with polyinosinic: Polycytidylic acid

Takaoka, Saori; Kamioka, Yuji; Takakura, Kanako; Baba, Ai; Shime, Hiroaki; Seya, Tsukasa; Matsuda, Michiyuki

Cancer Science 2016, 107(5):...

© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Live imaging of transforming growth factor-β activated kinase 1 activation in Lewis lung carcinoma 3LL cells implanted into syngeneic mice and treated with polyinosinic:polycytidylic acid

Saori Takaoka,1 Yuji Kamioka,1,2 Kanako Takakura,3 Ai Baba,4 Hiroaki Shime,5 Tsukasa Seya5 and Michiyuki Matsuda1,4

1Department of Pathology and Biology of Diseases, Graduate School of Medicine; 2Innovative Techno-Hub for Integrated Medical Bio-Imaging; 3Imaging Platform for Spatio-Temporal Regulation, Graduate School of Medicine; 4Laboratory of Bioimaging and Cell Signaling, Graduate School of Biostudies, Kyoto University, Kyoto; 5Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Key words
Forster (or fluorescence) resonance energy transfer, in vivo imaging, polyinosinic:polycytidylic acid (PolyI:C), transforming growth factor-β activated kinase 1, two-photon excitation microscopy

Correspondence
Yuji Kamioka, Department of Pathology and Biology of Diseases, Graduate School of Medicine, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. Tel: +81-75-753-9450; Fax: +81-75-753-4698; E-mail: ykamioka@lif.kyoto-u.ac.jp

Funding Information
Ministry of Education, Culture, Sports, and Science of Japan; Japan Agency for Medical Research and Development; Special Coordination Funds for Promoting Science and Technology; Japan Society for the Promotion of Science.

Received September 28, 2015; Revised February 1, 2016; Accepted February 28, 2016

Cancer Sci 107 (2016) 644–652
doi: 10.1111/cas.12923

Transforming growth factor-β activated kinase 1 (TAK1) has been shown to play a crucial role in cell death, differentiation, and inflammation. Here, we live-imaged robust TAK1 activation in Lewis lung carcinoma 3LL cells implanted into the s.c. tissue of syngeneic C57BL/6 mice and treated with polyinosinic:polycytidylic acid (PolyI:C). First, we developed and characterized a Forster resonance energy transfer-based biosensor for TAK1 activity. The TAK1 biosensor, named Eevee-TAK1, responded to stress-inducing reagents such as anisomycin, tumor necrosis factor-α, and interleukin-1β. The anisomycin-induced increase in Forster resonance energy transfer was abolished by the TAK1 inhibitor (5z)-7-oxozeaenol. Activity of TAK1 in 3LL cells was markedly increased by PolyI:C in the presence of macrophages. 3LL cells expressing Eevee-TAK1 were implanted into mice and observed through imaging window by two-photon excitation microscopy. During the growth of tumor, the 3LL cells at the periphery of the tumor showed higher TAK1 activity than the 3LL cells located at the center of the tumor, suggesting that cells at the periphery of the tumor mass were under stronger stress. Injection of PolyI:C, which is known to induce regression of the implanted tumors, induced marked and homogenous TAK1 activation within the tumor tissues. The effect of PolyI:C faded within 4 days. These observations suggest that Eevee-TAK1 is a versatile tool to monitor cellular stress in cancer tissues.

Transforming growth factor-β activated kinase 1 (TAK1) was first identified as a MAPK kinase downstream of TGF-β1 and has been shown to mediate Smad-independent TGF-β signaling to stress-responsive MAPK in a TRAF6-dependent manner, causing apoptosis and EMT.2,3 Importantly, TAK1 also functions as a hub to transmit inflammatory signals elicited by IL-1β and TNF-α to the nuclear factor-kB pathway.4,5 In the latter scenario, TAK1 prevents cells from apoptosis by multiple mechanisms.6–8 The anti-apoptotic role of TAK1 has also been shown genetically: TAK1-deficient mice are embryonic lethal9,10 or, in the case of conditional knockout, are suffering from dysfunction of the immune system or severe skin inflammation.11,12 Recently, however, it has been revealed that prolonged TAK1 activation induces another type of cell death, necroptosis, adding further complexity to the known functions of TAK1 in vivo.13

Chronic inflammation contributes greatly to the generation of the tumor microenvironment, which includes a variety of cell types such as tumor-associated macrophages and myeloid-derived suppressor cells.14,15 Pro-inflammatory cytokines such as TNF-α and IL-1β are the major players in fostering generation of the tumor microenvironment in chronic inflammation.14,16 Accordingly, TAK1 has been shown to promote tumor growth in various ways. For example, TAK1 is essential for TNF-α-mediated metastasis of colon or breast cancer cells.17,18 It is also required to inhibit apoptosis in KRas-transformed cells.19 In this context, it is worth noting that tumor-associated macrophages and myeloid-derived suppressor cells have been shown to be converted into tumoricidal effectors by RNA adjuvant therapy, with TNF-α and IL-1β again acting as the major mediators.20 Studies are therefore needed to determine how the inflammatory cytokine signaling pathway is regulated in an in vivo setting.

Genetically encoded biosensors based on fluorescent proteins and FRET have been developed in order to visualize the subcellular activities of signaling molecules.21,22 Recent progress has enabled us to follow the activities of small GTPases and protein kinases for several days under a microscope, opening a

© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
new window into the signal transduction of cancer cells. For example, it has been shown that glioma cells exhibit marked heterogeneity in Rac1 activity and their levels of Rac1 activity have been correlated to their invasion capacities. More recently, a FRET biosensor for ERK was used to investigate how melanoma cells build a niche to acquire drug tolerance.

Here we report a novel FRET biosensor for TAK1 activity, called Eevee-TAK1, based on the optimized backbone. Lewis lung carcinoma cells expressing Eevee-TAK1 were implanted s.c. into syngeneic mice and observed for 5 days through an imaging window by two-photon excitation microscopy. We found that TAK1 activity was higher at the invading front of the tumor tissues. Treatment with PolyI:C, which drives macrophages to secrete IL-1β and TNF-α, was found to evoke strong TAK1 activation diffusely in the tumor tissues. The combination of FRET biosensors and in vivo imaging will help us to untangle signaling pathways in living tissue.

Materials and Methods

Plasmids. Construction and stable expression of the FRET biosensor were carried out as described previously. The 3592NES FRET biosensor was based on the optimized Eevee backbone, which was comprised of the optimized fluorescent protein pair, YPet and ECFP, a long flexible EV-linker (116 a.a.), an FHA1 phospho-threonine-binding domain from yeast Rad53, a substrate sequence, and the NES from HIV-1 rev protein (LQLPPLERLTLD). The substrate sequence consisted of a.a. 276–295 of human cyclin D1 (EEEEEV-DLACCTPTDVRDVI), in which the +3 residue from the target phosphorylation site Thr286 (underlined) was changed to G. An expression vector for an active mutant of TAK1, TAK1-TAB, was kindly provided by Hiroaki Sakurai. The plasmid was transfected into HeLa cells expressing 3592NES with 293fectin according to the manufacturer’s protocol (Thermo Fisher Scientific, Waltham, MA, USA). The shRNA sequences inserted into pLKO.1-TRC are shown in Table 1. Negative control vector containing scrambled shRNA sequences inserted into pLKO.1-TRC (Manassas, VA, USA) and cultured with RPMI-1640 medium containing 10% FBS and penicillin–streptomycin at 37°C. Lewis lung carcinoma (3LL) cells were maintained in RPMI-1640 medium containing 10% FBS and penicillin–streptomycin at 37°C. 4T1 tumor cells were purchased from ATCC (Manassas, VA, USA) and cultured with RPMI-1640 medium containing 10% FBS and penicillin–streptomycin at 37°C. Bone marrow cells were collected from 8 to 12-week-old C57BL/6 mice. Monocyte subsets were enriched by using an EasySep mouse monocyte enrichment kit (Stemcell Technologies, Vancouver, BC, Canada). Isolated monocytes were maintained in RPMI-1640 medium containing 10% FBS and penicillin–streptomycin at 37°C. 4T1 tumor cells were purchased from ATCC (Manassas, VA, USA) and cultured with RPMI-1640 medium containing 10% FBS and penicillin–streptomycin at 37°C.

Preparation of macrophages. Bone marrow cells were collected from 8 to 12-week-old C57BL/6 mice. Monocyte subsets were enriched by using an EasySep mouse monocyte enrichment kit (Stemcell Technologies, Vancouver, BC, Canada). Isolated monocytes were maintained in RPMI-1640 medium containing 10% FBS and penicillin–streptomycin at 37°C. 4T1 tumor cells were purchased from ATCC (Manassas, VA, USA) and cultured with RPMI-1640 medium containing 10% FBS and penicillin–streptomycin at 37°C.

Epifluorescence microscopy of tissue culture cells. Förster (or fluorescence) resonance energy transfer imaging with an inverted epifluorescence microscope was carried out essentially as described previously. Cells were plated on 35-mm glass-base dishes, cultured for 24 h, and starved for 1 h in phenol red-free M199 (Thermo Fisher Scientific) containing 0.1% BSA. Cells were observed with an IX81 inverted microscope (Olympus, Tokyo, Japan) equipped with an Odyssey Infrared scanner (LI-COR) and analyzed by using the Odyssey imaging software.

Cell culture. HeLa cells were purchased from the Human Science Research Resources Bank (Sennan-shi, Japan) and maintained in DMEM (Wako) containing 10% FBS (Sigma-Aldrich) and penicillin–streptomycin (Nacalai Tesque, Kyoto, Japan) at 37°C in a humidified atmosphere containing 5% CO2.

Immunoblotting. HeLa, 4T1, and 3LL cells were lysed in SDS sample buffer (62.5 mM Tris-HCl [pH 6.8], 12% glycerol, 2% SDS, 0.004% bromophenol blue and 5% 2-mercaptoethanol). After sonication, the samples were separated by SDS-PAGE and transferred to PVDF membranes (Merck Millipore). After blocking with Odyssey blocking buffer (LI-COR) for 30 min, the membranes were incubated with primary antibodies diluted in Can Get Signal (Toyobo, Osaka, Japan), followed by secondary antibodies diluted in Odyssey blocking buffer. Proteins were detected by an Odyssey Infrared scanner (LI-COR) and analyzed by using the Odyssey imaging software.

Materials and Methods

Plasmids. Construction and stable expression of the FRET biosensor were carried out as described previously. The 3592NES FRET biosensor was based on the optimized Eevee backbone, which was comprised of the optimized fluorescent protein pair, YPet and ECFP, a long flexible EV-linker (116 a.a.), an FHA1 phospho-threonine-binding domain from yeast Rad53, a substrate sequence, and the NES from HIV-1 rev protein (LQLPPLERLTLD). The substrate sequence consisted of a.a. 276–295 of human cyclin D1 (EEEEEV-DLACCTPTDVRDVI), in which the +3 residue from the target phosphorylation site Thr286 (underlined) was changed to an Asp (italicized) to increase affinity to the FHA1 domain. Stable cell lines expressing the 3592NES FRET biosensors were established by transposon-mediated gene transfer as described previously. An expression vector for an active mutant of TAK1, TAK1-TAB, was kindly provided by Hiroaki Sakurai. The plasmid was transfected into HeLa cells expressing 3592NES with 293fectin according to the manufacturer’s protocol (Thermo Fisher Scientific, Waltham, MA, USA). The shRNA sequences inserted into pLKO.1-TRC are shown in Table 1. Negative control vector containing scrambled shRNA (#1864) was purchased from Addgene (Cambridge, MA, USA). The 4T1 cells or 3LL cells were transfected with pLKO-shTAK1 #1–#5 or scramble control (scr) by Lipofectamine 3000 (Thermo Fisher Scientific). Isolated monocytes were maintained in RPMI-1640 medium containing 10% FBS and penicillin–streptomycin at 37°C. Lewis lung carcinoma (3LL) cells were maintained in RPMI-1640 medium containing 10% FBS and penicillin–streptomycin at 37°C.

Preparation of macrophages. Bone marrow cells were collected from 8 to 12-week-old C57BL/6 mice. Monocyte subsets were enriched by using an EasySep mouse monocyte enrichment kit (Stemcell Technologies, Vancouver, BC, Canada). Isolated monocytes were maintained in RPMI-1640 medium containing 10% FBS, penicillin–streptomycin, and 10% L929 cell-conditioned medium at 37°C in a humidified atmosphere containing 5% CO2. Lewis lung carcinoma (3LL) cells were maintained in RPMI-1640 medium containing 10% FBS and penicillin–streptomycin at 37°C. 4T1 tumor cells were purchased from ATCC (Manassas, VA, USA) and cultured with RPMI-1640 medium containing 10% FBS and penicillin–streptomycin at 37°C.

Epifluorescence microscopy of tissue culture cells. Förster (or fluorescence) resonance energy transfer imaging with an inverted epifluorescence microscope was carried out essentially as described previously. Cells were plated on 35-mm glass-base dishes, cultured for 24 h, and starved for 1 h in phenol red-free M199 (Thermo Fisher Scientific) containing 0.1% BSA. Cells were observed with an IX81 inverted microscope (Olympus, Tokyo, Japan) equipped with a UPlanSapo 40 ×/0.95 dry objective lens (Olympus), PlanApo 60 ×/1.4 oil objective lens (Olympus), a CoolSNAP K4 charge-coupled

Antibodies and reagents. The following primary and secondary antibodies were used for immunoblotting analysis and
device camera (Roper Scientific, Tucson, AZ, USA), a CoolLED precisExcite LED illumination system (Molecular Devices, Sunnyvale, CA, USA), and an IX2-ZDC laser-based auto-focusing system (Olympus, Japan). Fluorescent images were acquired with the following filters purchased from Omega Optical (Brattleboro, VT, USA): an XF1071 440AF21 excitation filter, an XF2034 455DRLP dichroic mirror, and an XF3075 480AF30 emission filter for CFP, and an XF1071 440AF21 excitation filter, an XF2034 455DRLP dichroic mirror, and an XF3075 480AF30 emission filter for FRET.

Images were analyzed with Meta-Morph software (Universal Imaging, West Chester, PA, USA) as described previously. (29) Briefly, after background subtraction, FRET/CFP ratio images were generated in the intensity modulated display mode. Scale bar = 50 μm. (c,d) HeLa cells expressing 3592NES were stimulated with several stimuli-inducing reagents: 5 μg/mL anisomycin, 1 mM cyclic AMP (Mock), 1 μM TPA, 10 ng/mL epidermal growth factor (EGF), 270 ng/mL human tumor necrosis factor-α (hTNF-α), and 10 ng/mL mouse interleukin-1β (mIL-1β). (e) Representative time courses of FRET/CFP values. (d) Averages at 60 min of more than 20 cells under each condition from three independent experiments. (e) Lewis lung carcinoma 3LL cells expressing 3592NES were stimulated with 270 ng/mL TNF-α and 10 ng/mL IL-1β. (f) Representative time courses and averages at 60 min.
Characterization of 3592NES as a transducing growth factor-β activated kinase 1 (TAK1) biosensor. (a) HeLa cells expressing 3592NES were time-lapse imaged without or with 3 nM (5z)-7-oxygenoan 3592NES biosensor includes a 20-a.a. peptide derived from GSK-3β designed to monitor GSK-3β inhibitor, or 10 μM CHIR99021 (GSK-3β) inhibitor. The increase in Förster resonance energy transfer/cyan fluorescent protein (FRET/CFP) was scored at 60 min after the addition of 5 μg/mL anisomycin for more than 10 cells under each condition (bars indicate 5%; **p < 0.01). (b) Flow chart of the signaling pathway of TAK1. IL-1β, interleukin 1β; TNF-α, tumor necrosis factor-α. (c) HeLa cells expressing 3592NES were mock-transfected or transfected transiently with an active-TAK1 expression vector, and examined to determine their FRET/CFP values with a fluorescent microscope. A histogram for the FRET/CFP values is shown (mock, n = 188; active-TAK1, n = 81). (d) 4T1 cells were infected with lentiviruses carrying shRNA against TAK1. Cell lysates were analyzed by immunoblotting against TAK1. Tubulin expression was used for normalization. (e) The 3592NES-expressing 3LL cells were infected with lentiviruses carrying shRNA for TAK1 and stimulated with 10 ng/mL IL-1β (10 ng/mL). The increase in FRET/CFP 60 min after stimulation was scored (n ≥ 15; ****p < 0.0001). Scr, Scramble control.

Statistical analysis. P-values for normally distributed data were calculated with Student’s t-test or paired Student’s t-test for the evaluation of statistically significant differences. Otherwise, the Mann–Whitney U-test was used. Data analysis was carried out using Prism software (GraphPad Software, San Diego, CA, USA). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Results

Response of FRET biosensor 3592NES to stress-inducing reagents. The Eevee FRET biosensor 3592NES was originally designed to monitor GSK-3β activity in living cells. The 3592NES biosensor includes a 20-a.a. peptide derived from cyclin D1 peptide and known to be a phosphorylation site of GSK-3β (Fig. 1a). However, in our preliminary experiments, 3592NES did not respond to any GSK-3β-dependent stimuli or specific inhibitors against GSK-3β or cyclin-dependent protein kinases. During the course of characterization, however, we found that 3592NES responded markedly to anisomycin, suggesting that 3592NES may respond to stress-related kinases. In HeLa cells expressing 3592NES, anisomycin strongly increased the FRET/CFP ratio (Fig. 1b,c). Furthermore, stress-inducing cytokines, human TNF-α and mouse IL-1β, were also found to increase the FRET/CFP ratio in HeLa cells (Fig. 1c, d) and 3LL cells (Fig. 1e,f). In contrast, growth-promoting reagents such as epidermal growth factor or TPA did not increase the FRET/CFP ratio. Interestingly, the 3592NES-expressing HeLa cells responded more strongly to human TNF-α than mouse IL-1β, whereas 3LL cells responded more strongly to mouse IL-1β than human TNF-α (Fig. 1c-e). The expression of receptors for TNF-α and IL-1β in HeLa cells and 3LL cells was within a comparable range (Fig. S1A). Of note, HeLa cells were found to respond more strongly to human IL-1β than mouse IL-1β (Fig. S1B). This observation was confirmed by the immunoblotting for active p38 MAPK and JNK (Fig. S1C–E).

Requirement of TAK1 for stimulation-induced increase in FRET/CFP of 3592NES. To identify the kinase that phosphorylated 3592NES in response to stress-inducing stimuli, we searched for inhibitors that would abrogate the anisomycin-induced increase in FRET/CFP in 3592NES-expressing cells. Treatment with the TAK1 inhibitor, but not with other inhibitors for p38, JNK, IKK, or GSK-3β, completely suppressed the increase in FRET/CFP ratio (Fig. 2a). This result strongly suggested that 3592NES monitors TAK1 activity (Fig. 2b), or protein kinases downstream of TAK1. To confirm that 3592NES monitors TAK1 activity, we next examined the effect of an active TAK1. As TAK1 is known to be activated by binding to TAB 1, we used a TAK1–TAB 1 fusion protein as the
active-TAK1. HeLa cells transfected transiently with the expression vector for active-TAK1 showed a marked increase in the fraction of cells showing a high FRET/CFP ratio in comparison with the mock-transfected cells (Fig. 2c). Next, to knockdown TAK1, we prepared five shRNAs for TAK1 and used the two shRNAs (#2 and #4) that exhibited the highest knockdown efficiency in the following experiments (Fig. 2d). Depletion of TAK1, induced by the two shRNAs, suppressed the IL-1β-stimulated increment of the FRET/CFP ratio in 3LL cells (Fig. 2e). Based on these results demonstrating that 3592NES reflects cellular TAK1 activity, we renamed 3592NES as Eevee-TAK1 and used it in the following study.

**Activation of TAK1 in 3LL cells by PolyIC-stimulated macrophages.** With the Eevee-TAK1 biosensor in hand, we attempted to monitor the TAK1 activity of cancer cells, which are under the stress of immunological surveillance by the host. We used cells of the Lewis lung carcinoma cell line 3LL, which are known to be rejected by macrophages stimulated with double stranded RNA analog PolyIC (20). The 3LL cells stably-expressing Eevee-TAK1 were imaged in the presence or absence of macrophages derived from syngeneic C57B6/L mice. The activities of TAK1 in 3LL cells showed modest heterogeneity and changed during observation (Fig. 3a). By the addition of PolyIC to the co-culture of 3LL cells and macrophages, TAK1 activity in most 3LL cells increased within 740 min (Fig. 3b). For the precise evaluation of the effect of macrophages and PolyIC, we randomly chose more than 60 cells and measured the FRET/CFP ratio in each condition (Fig. 3b-1). Addition of PolyIC alone slightly increased TAK1 activity in 3LL cells (Fig. 3d). Co-culture with macrophages also increased TAK1 activity in 3LL cells within 740 min (Fig. 3e). The strongest TAK1 activation was observed when both PolyIC was added in the presence of macrophages (Fig. 3f). This observation is consistent with the previous report showing that PolyIC stimulates secretion of tumoricidal cytokines from macrophages.(20)

**In vivo imaging of TAK1 activity in implanted 3LL cells.** To examine the role of TAK1 in tumor growth, 3LL carcinoma cells expressing Eevee-TAK1 were implanted into the s.c. tissue of syngeneic C57BL/6 mice and observed repeatedly through an imaging window (Fig. 4a,b). First, an imaging window consisting of a cover glass and a magnet ring was surgically implanted under the skin of a mouse hind leg. After several days, when the inflammation caused by the surgery had subsided, 3LL cells were inoculated under the imaging window. Tumors grew to approximately 2 mm in diameter within 4 days. Before image acquisition, the magnet ring of the imaging window was used to level the cover glass to the fixing implement, which minimizes motion artifacts caused by heartbeats and breathing. Then the cancer tissues were observed by an upright two-photon excitation microscope to acquire FRET images. We could clearly distinguish each tumor cell and found that 3LL cells close to the surrounding host tissues exhibited high TAK1 activity (Fig. 4c). During 5 days observation, the high TAK1 activity was confined to the cells locating at the periphery of the tumor mass. To exclude the possibility that the gradient of the FRET/CFP ratio in the tumor tissue was an artifact, we used 3LL cells expressing a negative control FRET biosensor AKAREV-NC, in which the phosphorylation site of the FRET biosensor was...
in and around the allograft, we injected Alexa Fluor 647 anti-sue. To visualize the localization of the myeloid-derived cells may have caused the TAK1 activity gradient in the tumor tissue, among the tumor cells. We speculated that the enrichment of necrosis through cytokines secreted from myeloid-derived cells by the decrease of PolyI:C in the tissue, rather than by the adaptation of tumor cells to PolyI:C (Fig. 5a).

Because TAK1 responds to inflammatory stresses, we observed that inflammatory cytokines or direct interaction with antitumor immune cells caused TAK1 activation in the tumor reflected the localized recruitment of myeloid cells (Fig. 5d).

**Discussion**

In this study, we developed Eevee-TAK1, a new FRET-based biosensor monitoring TAK1 activity in living cells, and detected TAK1 activity at single-cell resolution. With Eevee-TAK1, we found that TAK1 activity was significantly higher in 3LL cells locating at the periphery of the tumor than in 3LL cells locating at the center of the tumor (Fig. 4c). Because TAK1 responds to inflammatory stresses, we speculated that inflammatory cytokines or direct interaction with antitumor immune cells caused TAK1 activation in the tumor cells located at the periphery of the tumor. However, against our expectation, F4/80-positive macrophages were observed diffusely in the tumor tissues (Fig. 5c). It is still possible that macrophages surrounding the tumor cells are more active than the macrophages within the tumor cells, which should be examined in a future study.

The high level of TAK1 activity in the peripheral tumor cells is reasonable if we consider the positive role of TAK1 in EMT. In agreement with this reasoning, we found that PolyI:C treatment causes significant TAK1 activation and EMT-like morphological changes of 3LL tumor cells at the periphery of the tumor cells (Fig. 5b). However, in our preliminary experiments, we failed to detect the induction of EMT markers such as E-cadherin, α-smooth muscle actin, Snail, or vimentin. Therefore, it is currently unknown whether the high

**Polyinosinic:polycytidylic acid-induced TAK1 activation in vivo.** Activation of innate immunity mediated by PolyI:C is known to induce the regression of 3LL cells in a syngeneic transplantation model. Therefore, we next examined the effect of PolyI:C on TAK1 activity. Twenty-four hours after injection, TAK1 activity was robustly elevated in almost all cells within the tumor tissue reflecting TAK1 activity, TAK1 inhibitor (5z)-7-oxozeaenol was injected below the imaging window (Fig. 4e). As expected, the TAK1 inhibitor robustly decreased the FRET/CFP ratio.

**Substitution of alanine.** As shown in Figure 4(d), the 3LL cells expressing AKAREV-NC did not show a remarkable gradient in the FRET/CFP ratio. To confirm that the high FRET/CFP ratio in the tumor tissue reflected TAK1 activity, TAK1 inhibitor (5z)-7-oxozeaenol was injected below the imaging window (Fig. 4e). As expected, the TAK1 inhibitor robustly decreased the FRET/CFP ratio.

**Discussion**

In this study, we developed Eevee-TAK1, a new FRET-based biosensor monitoring TAK1 activity in living cells, and detected TAK1 activity at single-cell resolution. With Eevee-TAK1, we found that TAK1 activity was significantly higher in 3LL cells locating at the periphery of the tumor than in 3LL cells locating at the center of the tumor (Fig. 4c). Because TAK1 responds to inflammatory stresses, we speculated that inflammatory cytokines or direct interaction with antitumor immune cells caused TAK1 activation in the tumor cells located at the periphery of the tumor. However, against our expectation, F4/80-positive macrophages were observed diffusely in the tumor tissues (Fig. 5c). It is still possible that macrophages surrounding the tumor cells are more active than the macrophages within the tumor cells, which should be examined in a future study.

The high level of TAK1 activity in the peripheral tumor cells is reasonable if we consider the positive role of TAK1 in EMT. In agreement with this reasoning, we found that PolyI:C treatment causes significant TAK1 activation and EMT-like morphological changes of 3LL tumor cells at the periphery of the tumor cells (Fig. 5b). However, in our preliminary experiments, we failed to detect the induction of EMT markers such as E-cadherin, α-smooth muscle actin, Snail, or vimentin. Therefore, it is currently unknown whether the high
TAK1 activity at the peripheral region of the tumor is related to EMT.

Phosphorylation of Thr286 of cyclin D1 plays a critical role in its cell cycle-dependent degradation. Originally, GSK-3β was believed to be responsible for Thr286 phosphorylation, but a later study showed that the checkpoint kinases ATR and ATM primarily phosphorylate Thr286 during the cell cycle. More recently, DYRKs have also been shown to phosphorylate cyclin D1 on Thr286 and regulate the cell cycle. We failed to detect cell cycle-dependent changes in the FRET signal in HeLa cells expressing 3592NES and regulate the cell cycle. Moreover, none of the inhibitors against GSK-3β, ATM/ATR, and DYRKs suppressed the anisomycin- or TNF-α-induced increase in the FRET signal of the 3592NES TAK1 biosensor. Nevertheless, we should keep in mind that these observations do not negate the possibility that GSK-3β, ATM/ATR, and DYRKs may contribute to the FRET signal in the TAK1 biosensor-expressing cells under different conditions.

One of the most difficult tasks in the development of a FRET biosensor for a protein kinase is the selection of a substrate peptide that is specific to the protein kinase of interest. With the ongoing progress in phospho-proteomics, more than 100,000 human protein phosphorylation sites are now deposited in PhosphoSitePlus and other databases. Recently, substrate databases of protein kinases have also been constructed by a novel method named KISS. These bidirectional approaches will help identify the consensus phosphorylation sequence of each protein kinase, which in turn will assist in the development of FRET biosensors for protein kinases. Although a consensus phosphorylation sequence of TAK1 was reported previously, most of the known substrates did not match this consensus sequence (Table S1). Therefore, it remains unknown why the amino acid sequence encompassing Thr286 of cyclin D1 served as an effective sensor for TAK1 activity. Moreover, in our experience, most of the reported consensus sequences for the protein kinases were not sufficiently specific for the individual kinases. For example, in the case of the FRET biosensor for ERK and JNK, in addition to the consensus phosphorylation sequences, docking sequences are required for the endowment of specificity to the biosensors. Therefore, the cyclin D1 sequence used in Eevee-TAK1 may coincidentally include the docking sequence to TAK1.

In conclusion, by using our newly developed TAK1 biosensor and an imaging window for in vivo imaging, the states of stress in tumor cells could be visualized for several days or more. This technique should open a new window onto the spatiotemporal effects of antitumor drugs during the induction of tumor necrosis.

Fig. 5. Polyinosinic:polycytidylic acid (PolyI:C)-induced transforming growth factor-β activated kinase 1 (TAK1) activation in vivo. 3LL Lewis lung carcinoma cells expressing 3592NES were implanted below the imaging window. (a) Förster resonance energy transfer (FRET) images from days 0 to 8. Subcutaneous injection of 200 μg PolyI:C was carried out on day 0, just after image acquisition, and day 7. (b) FRET/cyan fluorescent protein ratio was plotted along the white lines in (a). Asterisks indicate the origin. (c) Regions marked by white boxes in (a) are enlarged to show PolyI:C-induced morphological changes. (d) Macrophages beneath the window were marked with Alexa Fluor 647 anti-mouse F4/80 antibody. Right panel, merged image of white-boxed regions.
Acknowledgments

We thank Kosuke Yusa, Allan Bradly, Hiroaki Sakurai, Tohru Ishitani, and Kunhiro Matsumoto for the plasmids, and the members of the Matsuda Laboratory for their technical assistance. This work was supported by the Platform Project for Supporting Drug Discovery and Life Science Research (Platform for Dynamic Approaches to Living System) of the Ministry of Education, Culture, Sports, and Science of Japan, by the Japan Agency for Medical Research and Development, by the Innovative Techno-Hub for Integrated Medical Bio-imaging Project of the Special Coordination Funds for Promoting Science and Technology, and by a Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Young Scientists (B) 23701053 and 26830070.

Disclosure Statement

The authors have no conflict of interest.

References


Abbreviations

a.a. amino acid
ATM ataxia-telangiectasia mutated
ATR ATM and RAD3-related
CYP cytochrome P450
DGKR dual-specificity tyrosine phosphorylation-regulated kinase
EMT epithelial mesenchymal transition
IL-1beta interleukin 1-beta
GSK-3beta glycogen synthase kinase-3-beta
NES nuclear export signal
Poly-C polynucleoside-polycytidylic acid
TAB1 TAK1-binding protein 1
TAK TGF-beta activated kinase 1
TAK1 transforming growth factor-beta
TNF-a tumor necrosis factor-a


Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

Fig. S1. Detection of species-specific responses to tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β).
Table S1. Consensus phosphorylation sequence of transforming growth factor-β activated kinase 1 (TAK1).